Everolimus in combination with mycophenolate mofetil aspre- and post-transplantation immunosuppression after nonmyeloablative hematopoietic stem cell transplantation in canine littermates

Biology of Blood and Marrow Transplantation

Volumn 20, Issue 9, 2014, Pages 1301-1306

  Machka, Christoph ^a   Lange, Sandra ^a   Werner, Juliane ^a   Wacke, Rainer ^a   Killian, Doreen ^a   Knueppel, Anne ^a   Knuebel, Gudrun ^a   Vogel, Heike ^a   Lindner, Iris ^a   Roolf, Catrin ^a   Murua Escobar, Hugo ^a   Junghanss, Christian ^a  

^a UNIVERSITY OF ROSTOCK   (Germany)

Author keywords

Allogeneic hematopoietic stem cell transplantation; Dogs; Everolimus; Nonmyeloablative conditioning; Pharmacokinetics

Indexed keywords

EVEROLIMUS; IMMUNOSUPPRESSIVE AGENT; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RAPAMYCIN;

ANALOGS AND DERIVATIVES; ANIMAL; CHIMERA; DOG; HEMATOPOIETIC STEM CELL TRANSPLANTATION; IMMUNOSUPPRESSIVE TREATMENT; MULTIMODALITY CANCER THERAPY; PROCEDURES;

ANIMALS; CHIMERISM; COMBINED MODALITY THERAPY; DOGS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; IMMUNOSUPPRESSION; IMMUNOSUPPRESSIVE AGENTS; MYCOPHENOLIC ACID; SIROLIMUS;

EID: 84905569746     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2014.06.004     Document Type: Article

References (25)

1. Chan S. Targeting the mammalian target of rapamycin (mTOR): a new approach to treating cancer. Br J Cancer 2004, 91:1420-1424.
2. Hogan W.J., Little M.-T., Zellmer E., et al. Postgrafting immunosuppression with sirolimus and cyclosporine facilitates stable mixed hematopoietic chimerism in dogs given sublethal total body irradiation before marrow transplantation from DLA-identical littermates. Biol Blood Marrow Transplant 2003, 9:489-495.
3. Sorror M.L., Leisenring W., Mielcarek M., et al. Intensified postgrafting immunosuppression failed to assure long-term engraftment of dog leukocyte antigen-identical canine marrow grafts after 1 gray total body irradiation. Transplantation 2008, 85:1023-1029.
4. Baselga J., Campone M., Piccart M., et al. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. NEngl J Med 2012, 366:520-529.
5. Haritunians T., Mori A., O'Kelly J., et al. Antiproliferative activity of RAD001 (everolimus) as a single agent and combined with other agents in mantle cell lymphoma. Leukemia 2007, 21:333-339.
6. Lorber M.I., Mulgaonkar S., Butt K.M.H., et al. Everolimus versus mycophenolate mofetil in the prevention of rejection in de novo renal transplant recipients: a 3-year randomized, multicenter, phase III study. Transplantation 2005, 80:244-252.
7. Budde K., Becker T., Arns W., et al. Everolimus-based, calcineurin-inhibitor-free regimen in recipients of de-novo kidney transplants: an open-label, randomised, controlled trial. Lancet 2011, 377:837-847.
8. Manzia T.M., Sforza D., Angelico R., et al. Everolimus and enteric-coated mycophenolate sodium ab initio after liver transplantation: midterm results. Transplant Proc 2012, 44:1942-1945.
9. Albano L., Alamartine E., Toupance O., et al. Conversion from everolimus with low-exposure cyclosporine to everolimus with mycophenolate sodium maintenance therapy in kidney transplant recipients: a randomized, open-label multicenter study. Ann Transplant 2012, 17:58-67.
10. Eisen H.J., Tuzcu E.M., Dorent R., et al. Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant recipients. NEngl J Med 2003, 349:847-858.
11. Platzbecker U., von Bonin M., Goekkurt E., et al. Graft-versus-host disease prophylaxis with everolimus and tacrolimus is associated with a high incidence of sinusoidal obstruction syndrome and microangiopathy: results of the EVTAC trial. Biol Blood Marrow Transplant 2009, 15:101-108.
12. Junghanss C., Rathsack S., Wacke R., et al. Everolimus in combination with cyclosporin a as pre- and posttransplantation immunosuppressive therapy in nonmyeloablative allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2012, 18:1061-1068.
13. Schleuning M., Judith D., Jedlickova Z., et al. Calcineurin inhibitor-free GVHD prophylaxis with sirolimus, mycophenolate mofetil and ATG in Allo-SCT for leukemia patients with high relapse risk: an observational cohort study. Bone Marrow Transplant 2009, 43:717-723.
14. Wagner J.L., Burnett R.C., DeRose S.A., et al. Histocompatibility testing of dog families with highly polymorphic microsatellite markers. Transplantation 1996, 62:876-877.
15. Pascual J. Everolimus in clinical practice-renal transplantation. Nephrol Dial Transplant 2006, 21(Suppl 3):iii18-23.
16. Hilgendorf I., Weirich V., Zeng L., et al. Canine haematopoietic chimerism analyses by semiquantitative fluorescence detection of variable number of tandem repeat polymorphism. Vet Res Commun 2005, 29:103-110.
17. Campone M., Levy V., Bourbouloux E., et al. Safety and pharmacokinetics of paclitaxel and the oral mTOR inhibitor everolimus in advanced solid tumours. Br J Cancer 2009, 100:315-321.
18. Lange S., Mueller S.C., Altmann S., et al. Pharmacokinetics of oral mycophenolate mofetil in combination with CsA in dogs after nonmyeloablative allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant 2008, 41:667-674.
19. Lupu M., McCune J.S., Kuhr C.S., et al. Pharmacokinetics of oral mycophenolate mofetil in dog: bioavailability studies and the impact of antibiotic therapy. Biol Blood Marrow Transplant 2006, 12:1352-1354.
20. Staatz C.E., Tett S.E. Clinical pharmacokinetics and pharmacodynamics of mycophenolate in solid organ transplant recipients. Clin Pharmacokinet 2007, 46:13-58.
21. Lange S., Altmann S., Brandt B., et al. Investigation of immunological approaches to enhance engraftment in a 1 Gy TBI canine hematopoietic stem cell transplantation model. Exp Hematol 2009, 37:143-150.
22. Storb R., Yu C., Wagner J.L., et al. Stable mixed hematopoietic chimerism in DLA-identical littermate dogs given sublethal total body irradiation before and pharmacological immunosuppression after marrow transplantation. Blood 1997, 89:3048-3054.
23. Kovarik J.M., Kahan B.D., Kaplan B., et al. Longitudinal assessment of everolimus in de novo renal transplant recipients over the first post-transplant year: pharmacokinetics, exposure-response relationships, and influence on cyclosporine. Clin Pharmacol Ther 2001, 69:48-56.
24. Martins F., de Oliveira M.A., Wang Q., et al. Areview of oral toxicity associated with mTOR inhibitor therapy in cancer patients. Oral Oncol 2013, 49:293-298.
25. Ferté C., Paci A., Zizi M., et al. Natural history, management and pharmacokinetics of everolimus-induced-oral ulcers: insights into compliance issues. Eur J Cancer 2011, 47:2249-2255.